Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2002-05-01

AUTHORS

J Mehta, R Powles, B Sirohi, J Treleaven, S Kulkarni, R Saso, D Tait, S Singhal

ABSTRACT

It is not known if donor–recipient ABO blood group incompatibility contributes to graft-versus-leukemia after allogeneic BMT. One hundred and nineteen patients with acute myeloid leukemia in first remission underwent non-T cell-depleted marrow allografts from HLA-identical siblings after TBI and cyclophosphamide (n = 72) or melphalan (n = 47). GVHD prophylaxis comprised cyclosporine alone or cyclosporine-methotrexate. Twenty-two patients relapsed at 3–46 months (median 7): 18 of 76 patients with ABO-matched donors and four of 43 patients with ABO-mismatched donors (actuarial 5-year probabilities 33 ± 6% vs 12 ± 6%; P = 0.028). The incidence of acute and chronic GVHD was not affected by ABO mismatch. The following factors were studied in Cox analysis for effect on outcome: gender, age, FAB subtype, ABO mismatch, CR–transplant interval, conditioning, TBI dose, nucleated cell dose, lymphocyte recovery, acute GVHD, and chronic GVHD. Donor–recipient ABO match was the only factor independently associated with a higher risk of relapse (RR = 3.7; 95% Cl, 1.1–12.6; P = 0.04). ABO mismatch was also associated with superior overall and disease-free survivals. We conclude that ABO incompatibility may influence relapse rates and survival favorably after allogeneic BMT. It is not known if this holds true for allogeneic blood stem cell transplants. More... »

PAGES

853-859

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bmt.1703545

DOI

http://dx.doi.org/10.1038/sj.bmt.1703545

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1044989458

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12058235


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ABO Blood-Group System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erythrocyte Transfusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Histocompatibility", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Donors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Homologous", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mehta", 
        "givenName": "J", 
        "id": "sg:person.01145473407.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145473407.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Powles", 
        "givenName": "R", 
        "id": "sg:person.07441106644.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07441106644.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sirohi", 
        "givenName": "B", 
        "id": "sg:person.0646557041.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646557041.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Treleaven", 
        "givenName": "J", 
        "id": "sg:person.016453351654.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016453351654.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kulkarni", 
        "givenName": "S", 
        "id": "sg:person.0776532017.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776532017.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saso", 
        "givenName": "R", 
        "id": "sg:person.0700414221.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700414221.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tait", 
        "givenName": "D", 
        "id": "sg:person.0753037103.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753037103.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Department of Internal Medicine, Hematopoietic Stem Cell Transplant Program, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK", 
            "Division of Hematology/Oncology, Department of Internal Medicine, Hematopoietic Stem Cell Transplant Program, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singhal", 
        "givenName": "S", 
        "id": "sg:person.01224530271.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224530271.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bmt.1700720", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047293419", 
          "https://doi.org/10.1038/sj.bmt.1700720"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2002-05-01", 
    "datePublishedReg": "2002-05-01", 
    "description": "It is not known if donor\u2013recipient ABO blood group incompatibility contributes to graft-versus-leukemia after allogeneic BMT. One hundred and nineteen patients with acute myeloid leukemia in first remission underwent non-T cell-depleted marrow allografts from HLA-identical siblings after TBI and cyclophosphamide (n = 72) or melphalan (n = 47). GVHD prophylaxis comprised cyclosporine alone or cyclosporine-methotrexate. Twenty-two patients relapsed at 3\u201346 months (median 7): 18 of 76 patients with ABO-matched donors and four of 43 patients with ABO-mismatched donors (actuarial 5-year probabilities 33 \u00b1 6% vs 12 \u00b1 6%; P = 0.028). The incidence of acute and chronic GVHD was not affected by ABO mismatch. The following factors were studied in Cox analysis for effect on outcome: gender, age, FAB subtype, ABO mismatch, CR\u2013transplant interval, conditioning, TBI dose, nucleated cell dose, lymphocyte recovery, acute GVHD, and chronic GVHD. Donor\u2013recipient ABO match was the only factor independently associated with a higher risk of relapse (RR = 3.7; 95% Cl, 1.1\u201312.6; P = 0.04). ABO mismatch was also associated with superior overall and disease-free survivals. We conclude that ABO incompatibility may influence relapse rates and survival favorably after allogeneic BMT. It is not known if this holds true for allogeneic blood stem cell transplants.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bmt.1703545", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096890", 
        "issn": [
          "0268-3369", 
          "1476-5365"
        ], 
        "name": "Bone Marrow Transplantation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "keywords": [
      "acute myeloid leukemia", 
      "ABO mismatch", 
      "chronic GVHD", 
      "allogeneic BMT", 
      "ABO incompatibility", 
      "myeloid leukemia", 
      "allogeneic blood stem cell transplants", 
      "first remission acute myeloid leukemia", 
      "allogeneic bone marrow transplantation", 
      "blood stem cell transplant", 
      "ABO blood group incompatibility", 
      "donor-recipient ABO incompatibility", 
      "nucleated cell dose", 
      "HLA-identical siblings", 
      "disease-free survival", 
      "stem cell transplant", 
      "bone marrow transplantation", 
      "blood group incompatibility", 
      "GVHD prophylaxis", 
      "acute GVHD", 
      "first remission", 
      "TBI dose", 
      "marrow allografts", 
      "Cox analysis", 
      "FAB subtypes", 
      "lymphocyte recovery", 
      "relapse rate", 
      "cell transplant", 
      "marrow transplantation", 
      "ABO match", 
      "cell dose", 
      "high risk", 
      "superior overall", 
      "patients", 
      "GVHD", 
      "leukemia", 
      "only factor", 
      "relapse", 
      "BMT", 
      "dose", 
      "survival", 
      "ABO", 
      "remission", 
      "prophylaxis", 
      "cyclophosphamide", 
      "cyclosporine", 
      "allografts", 
      "melphalan", 
      "transplantation", 
      "transplant", 
      "graft", 
      "TBI", 
      "donors", 
      "incidence", 
      "subtypes", 
      "months", 
      "Overall", 
      "outcomes", 
      "age", 
      "factors", 
      "risk", 
      "siblings", 
      "gender", 
      "interval", 
      "recovery", 
      "rate", 
      "conditioning", 
      "effect", 
      "incompatibility", 
      "analysis", 
      "mismatch", 
      "match"
    ], 
    "name": "Does donor\u2013recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?", 
    "pagination": "853-859", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1044989458"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bmt.1703545"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12058235"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bmt.1703545", 
      "https://app.dimensions.ai/details/publication/pub.1044989458"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_359.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bmt.1703545"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703545'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703545'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703545'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703545'


 

This table displays all metadata directly associated to this object as RDF triples.

246 TRIPLES      21 PREDICATES      112 URIs      103 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bmt.1703545 schema:about N17408a4eba45414a9b0380c5afa537a2
2 N246e0aa810774205bc465ac9131c9fb3
3 N3fa259042f90424f8c93558b37615858
4 N54334800347d407f9e5341a843f83e80
5 N7b2c7160960b4ab09db2b24b871f0283
6 N8bdac1a0c15e4371ae1078f2222be319
7 N8eb8ca5ff37e481b9ca4f37a48afbef1
8 N99ba5ea14912482f8cb05057edc39cfe
9 Nb439ee77d09c4e1b81b97bb776be5aea
10 Ndf895966a1934fc9931302ae7d740f2c
11 Ne80768137fdc4ba9a6ca4641d850e4f8
12 Nf22a15f038c74148aa4c923e7c3b26f4
13 Nf3e3ccc803494b18846bf567e91c644f
14 Nfd342d012b0e435891a77754a172d752
15 anzsrc-for:11
16 anzsrc-for:1102
17 schema:author N08fe324913ce4bc9849967b3edd15d57
18 schema:citation sg:pub.10.1038/sj.bmt.1700720
19 schema:datePublished 2002-05-01
20 schema:datePublishedReg 2002-05-01
21 schema:description It is not known if donor–recipient ABO blood group incompatibility contributes to graft-versus-leukemia after allogeneic BMT. One hundred and nineteen patients with acute myeloid leukemia in first remission underwent non-T cell-depleted marrow allografts from HLA-identical siblings after TBI and cyclophosphamide (n = 72) or melphalan (n = 47). GVHD prophylaxis comprised cyclosporine alone or cyclosporine-methotrexate. Twenty-two patients relapsed at 3–46 months (median 7): 18 of 76 patients with ABO-matched donors and four of 43 patients with ABO-mismatched donors (actuarial 5-year probabilities 33 ± 6% vs 12 ± 6%; P = 0.028). The incidence of acute and chronic GVHD was not affected by ABO mismatch. The following factors were studied in Cox analysis for effect on outcome: gender, age, FAB subtype, ABO mismatch, CR–transplant interval, conditioning, TBI dose, nucleated cell dose, lymphocyte recovery, acute GVHD, and chronic GVHD. Donor–recipient ABO match was the only factor independently associated with a higher risk of relapse (RR = 3.7; 95% Cl, 1.1–12.6; P = 0.04). ABO mismatch was also associated with superior overall and disease-free survivals. We conclude that ABO incompatibility may influence relapse rates and survival favorably after allogeneic BMT. It is not known if this holds true for allogeneic blood stem cell transplants.
22 schema:genre article
23 schema:isAccessibleForFree false
24 schema:isPartOf N3be38ae73c5b4156a19d9a8941c220f2
25 Nd05114cb63304f37a321fd6327be5ed7
26 sg:journal.1096890
27 schema:keywords ABO
28 ABO blood group incompatibility
29 ABO incompatibility
30 ABO match
31 ABO mismatch
32 BMT
33 Cox analysis
34 FAB subtypes
35 GVHD
36 GVHD prophylaxis
37 HLA-identical siblings
38 Overall
39 TBI
40 TBI dose
41 acute GVHD
42 acute myeloid leukemia
43 age
44 allogeneic BMT
45 allogeneic blood stem cell transplants
46 allogeneic bone marrow transplantation
47 allografts
48 analysis
49 blood group incompatibility
50 blood stem cell transplant
51 bone marrow transplantation
52 cell dose
53 cell transplant
54 chronic GVHD
55 conditioning
56 cyclophosphamide
57 cyclosporine
58 disease-free survival
59 donor-recipient ABO incompatibility
60 donors
61 dose
62 effect
63 factors
64 first remission
65 first remission acute myeloid leukemia
66 gender
67 graft
68 high risk
69 incidence
70 incompatibility
71 interval
72 leukemia
73 lymphocyte recovery
74 marrow allografts
75 marrow transplantation
76 match
77 melphalan
78 mismatch
79 months
80 myeloid leukemia
81 nucleated cell dose
82 only factor
83 outcomes
84 patients
85 prophylaxis
86 rate
87 recovery
88 relapse
89 relapse rate
90 remission
91 risk
92 siblings
93 stem cell transplant
94 subtypes
95 superior overall
96 survival
97 transplant
98 transplantation
99 schema:name Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
100 schema:pagination 853-859
101 schema:productId N1bcf6ffe215943c5887dabc6c94d912b
102 N231ed5bf7a0141e595a5c00ebefd618c
103 Nb5cf6636148a478c82acfc5c8a310b5a
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044989458
105 https://doi.org/10.1038/sj.bmt.1703545
106 schema:sdDatePublished 2022-10-01T06:32
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N66eb700ad0d54915bb9bca7e67e34650
109 schema:url https://doi.org/10.1038/sj.bmt.1703545
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N08fe324913ce4bc9849967b3edd15d57 rdf:first sg:person.01145473407.31
114 rdf:rest N9e14c815dabe4f68a1f61232753700e9
115 N17408a4eba45414a9b0380c5afa537a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Erythrocyte Transfusion
117 rdf:type schema:DefinedTerm
118 N1bcf6ffe215943c5887dabc6c94d912b schema:name doi
119 schema:value 10.1038/sj.bmt.1703545
120 rdf:type schema:PropertyValue
121 N231ed5bf7a0141e595a5c00ebefd618c schema:name pubmed_id
122 schema:value 12058235
123 rdf:type schema:PropertyValue
124 N23a6cd88773644c48b87648472f07297 rdf:first sg:person.0753037103.30
125 rdf:rest N261c67a9cd7d4103b2c326677da4ebaa
126 N246e0aa810774205bc465ac9131c9fb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Middle Aged
128 rdf:type schema:DefinedTerm
129 N261c67a9cd7d4103b2c326677da4ebaa rdf:first sg:person.01224530271.62
130 rdf:rest rdf:nil
131 N3be38ae73c5b4156a19d9a8941c220f2 schema:issueNumber 10
132 rdf:type schema:PublicationIssue
133 N3fa259042f90424f8c93558b37615858 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Transplantation, Homologous
135 rdf:type schema:DefinedTerm
136 N54334800347d407f9e5341a843f83e80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Humans
138 rdf:type schema:DefinedTerm
139 N563bef8040f2491cbd6d5c7dfc569c3c rdf:first sg:person.016453351654.93
140 rdf:rest Ncd56b5926ae94a10a57be6a6440d020a
141 N66eb700ad0d54915bb9bca7e67e34650 schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N6f8684628f774c418f979315e4b287b9 rdf:first sg:person.0646557041.74
144 rdf:rest N563bef8040f2491cbd6d5c7dfc569c3c
145 N7b2c7160960b4ab09db2b24b871f0283 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name ABO Blood-Group System
147 rdf:type schema:DefinedTerm
148 N8bdac1a0c15e4371ae1078f2222be319 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Tissue Donors
150 rdf:type schema:DefinedTerm
151 N8eb8ca5ff37e481b9ca4f37a48afbef1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Leukemia, Myeloid, Acute
153 rdf:type schema:DefinedTerm
154 N99ba5ea14912482f8cb05057edc39cfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Male
156 rdf:type schema:DefinedTerm
157 N9e14c815dabe4f68a1f61232753700e9 rdf:first sg:person.07441106644.42
158 rdf:rest N6f8684628f774c418f979315e4b287b9
159 Nb439ee77d09c4e1b81b97bb776be5aea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Adolescent
161 rdf:type schema:DefinedTerm
162 Nb5cf6636148a478c82acfc5c8a310b5a schema:name dimensions_id
163 schema:value pub.1044989458
164 rdf:type schema:PropertyValue
165 Nb6a2a6a31ef44b1984098de5401c573b rdf:first sg:person.0700414221.40
166 rdf:rest N23a6cd88773644c48b87648472f07297
167 Ncd56b5926ae94a10a57be6a6440d020a rdf:first sg:person.0776532017.05
168 rdf:rest Nb6a2a6a31ef44b1984098de5401c573b
169 Nd05114cb63304f37a321fd6327be5ed7 schema:volumeNumber 29
170 rdf:type schema:PublicationVolume
171 Ndf895966a1934fc9931302ae7d740f2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Remission Induction
173 rdf:type schema:DefinedTerm
174 Ne80768137fdc4ba9a6ca4641d850e4f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Histocompatibility
176 rdf:type schema:DefinedTerm
177 Nf22a15f038c74148aa4c923e7c3b26f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Bone Marrow Transplantation
179 rdf:type schema:DefinedTerm
180 Nf3e3ccc803494b18846bf567e91c644f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Adult
182 rdf:type schema:DefinedTerm
183 Nfd342d012b0e435891a77754a172d752 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Female
185 rdf:type schema:DefinedTerm
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
190 schema:name Cardiorespiratory Medicine and Haematology
191 rdf:type schema:DefinedTerm
192 sg:journal.1096890 schema:issn 0268-3369
193 1476-5365
194 schema:name Bone Marrow Transplantation
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01145473407.31 schema:affiliation grid-institutes:None
198 schema:familyName Mehta
199 schema:givenName J
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145473407.31
201 rdf:type schema:Person
202 sg:person.01224530271.62 schema:affiliation grid-institutes:grid.16753.36
203 schema:familyName Singhal
204 schema:givenName S
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224530271.62
206 rdf:type schema:Person
207 sg:person.016453351654.93 schema:affiliation grid-institutes:None
208 schema:familyName Treleaven
209 schema:givenName J
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016453351654.93
211 rdf:type schema:Person
212 sg:person.0646557041.74 schema:affiliation grid-institutes:None
213 schema:familyName Sirohi
214 schema:givenName B
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646557041.74
216 rdf:type schema:Person
217 sg:person.0700414221.40 schema:affiliation grid-institutes:None
218 schema:familyName Saso
219 schema:givenName R
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700414221.40
221 rdf:type schema:Person
222 sg:person.07441106644.42 schema:affiliation grid-institutes:None
223 schema:familyName Powles
224 schema:givenName R
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07441106644.42
226 rdf:type schema:Person
227 sg:person.0753037103.30 schema:affiliation grid-institutes:None
228 schema:familyName Tait
229 schema:givenName D
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753037103.30
231 rdf:type schema:Person
232 sg:person.0776532017.05 schema:affiliation grid-institutes:None
233 schema:familyName Kulkarni
234 schema:givenName S
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776532017.05
236 rdf:type schema:Person
237 sg:pub.10.1038/sj.bmt.1700720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047293419
238 https://doi.org/10.1038/sj.bmt.1700720
239 rdf:type schema:CreativeWork
240 grid-institutes:None schema:alternateName Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK
241 schema:name Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK
242 rdf:type schema:Organization
243 grid-institutes:grid.16753.36 schema:alternateName Division of Hematology/Oncology, Department of Internal Medicine, Hematopoietic Stem Cell Transplant Program, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
244 schema:name Division of Hematology/Oncology, Department of Internal Medicine, Hematopoietic Stem Cell Transplant Program, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
245 Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK
246 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...